What is the current valuation of the India neuropathic pain market as of 2024?

The market valuation was $487.5 Million in 2024. Read More

What is the projected market size for the India neuropathic pain market by 2035?

The projected valuation for 2035 is $1,038.0 Million. Read More

What is the expected CAGR for the market during the forecast period 2025 - 2035?

The expected CAGR is 7.11% during the forecast period 2025 - 2035. Read More

Which segment of neuropathic pain had the highest valuation in 2024?

Diabetic Neuropathy had the highest valuation at $150.0 Million in 2024. Read More

What are the key treatment types in the India neuropathic pain market?

Key treatment types include Medications, Physical Therapy, Surgical Procedures, and Electrical Stimulation. Read More

How much was the valuation for Medications in the treatment type segment in 2024?

The valuation for Medications was $200.0 Million in 2024. Read More

What is the expected growth for the Home Care segment by 2035?

The Home Care segment is projected to grow to $524.5 Million by 2035. Read More

Which companies are leading the India neuropathic pain market?

Key players include Pfizer Inc, Johnson & Johnson, and Novartis AG among others. Read More

What is the valuation range for Trigeminal Neuralgia in 2024?

The valuation range for Trigeminal Neuralgia was $80.0 Million to $180.0 Million in 2024. Read More

What routes of administration are prevalent in the market?

Prevalent routes of administration include Oral, Topical, and Injectable. Read More

India Neuropathic Pain Market

ID: MRFR/HC/47673-HCR

200 Pages

Nidhi Mandole

Last Updated: April 08, 2026

India Neuropathic Pain Market Research Report By Type of Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Trigeminal Neuralgia, Chemotherapy-Induced Peripheral Neuropathy), By Treatment Type (Medications, Physical Therapy, Surgical Procedures, Electrical Stimulation), By Route of Administration (Oral, Topical, Injectable) and By End User (Hospitals, Clinics, Home Care) - Growth & Industry Forecast 2025 To 2035

India Neuropathic Pain Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Construction, BY Type of Neuropathic Pain (USD Million) | |
  1. 4.1.1 Diabetic Neuropathy | |
  2. 4.1.2 Postherpetic Neuralgia | |
  3. 4.1.3 Trigeminal Neuralgia | |
  4. 4.1.4 Chemotherapy-Induced Peripheral Neuropathy |
2. 4.2 Construction, BY Treatment Type (USD Million) | |
  1. 4.2.1 Medications | |
  2. 4.2.2 Physical Therapy | |
  3. 4.2.3 Surgical Procedures | |
  4. 4.2.4 Electrical Stimulation |
3. 4.3 Construction, BY Route of Administration (USD Million) | |
  1. 4.3.1 Oral | |
  2. 4.3.2 Topical | |
  3. 4.3.3 Injectable |
4. 4.4 Construction, BY End User (USD Million) | |
  1. 4.4.1 Hospitals | |
  2. 4.4.2 Clinics | |
  3. 4.4.3 Home Care 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Construction | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Pfizer Inc (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Johnson & Johnson (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Boehringer Ingelheim (DE) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 AstraZeneca (GB) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Novartis AG (CH) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Teva Pharmaceutical Industries Ltd (IL) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Eli Lilly and Company (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 GSK (GB) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Sanofi (FR) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 INDIA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
6. 6.3 INDIA MARKET ANALYSIS BY TREATMENT TYPE |
7. 6.4 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
8. 6.5 INDIA MARKET ANALYSIS BY END USER |
9. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION |
10. 6.7 RESEARCH PROCESS OF MRFR |
11. 6.8 DRO ANALYSIS OF CONSTRUCTION |
12. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION |
13. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION |
14. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION |
15. 6.12 CONSTRUCTION, BY TYPE OF NEUROPATHIC PAIN, 2024 (% SHARE) |
16. 6.13 CONSTRUCTION, BY TYPE OF NEUROPATHIC PAIN, 2024 TO 2035 (USD Million) |
17. 6.14 CONSTRUCTION, BY TREATMENT TYPE, 2024 (% SHARE) |
18. 6.15 CONSTRUCTION, BY TREATMENT TYPE, 2024 TO 2035 (USD Million) |
19. 6.16 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
20. 6.17 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million) |
21. 6.18 CONSTRUCTION, BY END USER, 2024 (% SHARE) |
22. 6.19 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million) |
23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
24. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
25. 7.2 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Million) | |
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million) | |
  4. 7.2.4 BY END USER, 2025-2035 (USD Million) |
26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
27. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

India Construction Market Segmentation

Construction By Type of Neuropathic Pain (USD Million, 2025-2035)

Diabetic Neuropathy
Postherpetic Neuralgia
Trigeminal Neuralgia
Chemotherapy-Induced Peripheral Neuropathy

Construction By Treatment Type (USD Million, 2025-2035)

Medications
Physical Therapy
Surgical Procedures
Electrical Stimulation

Construction By Route of Administration (USD Million, 2025-2035)

Oral
Topical
Injectable

Construction By End User (USD Million, 2025-2035)

Hospitals
Clinics
Home Care

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓